LEXINGTON, Mass. , Nov. 14, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that Curis will report emavusertib and BTKi clinical data in Primary CNS Lymphoma (PCNSL) and Secondary CNS Lymphoma (SCNSL) in three presentations and preclinical data on emavusertib in an oral presentation at the 30th Annual Meeting of the Society for Neuro-Oncology (SNO) on November 19 ...

Core Viewpoint - Curis, Inc. is set to report its second quarter 2025 financial and operational results on August 5, 2025, with a conference call scheduled for the same day [1]. Company Overview - Curis, Inc. is a biotechnology company focused on developing emavusertib (CA-4948), an orally available small molecule IRAK4 inhibitor [3]. - Emavusertib is currently being evaluated in multiple clinical studies, including the TakeAim Lymphoma Phase 1/2 study for patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) and the TakeAim Leukemia Phase 1/2 study for patients with relapsed/refractory acute myeloid leukemia (AML) [3]. - The drug has received Orphan Drug Designation from the U.S. FDA for the treatment of PCNSL, AML, and myelodysplastic syndrome (MDS) [3]. - Curis holds exclusive licensing rights to emavusertib through a collaboration with Aurigene established in 2015 [3]. - The company has licensed its rights to Erivedge® to Genentech, which is commercializing the drug for advanced basal cell carcinoma [3].